Kerx’s third quarter results show that business is back to normal again. The company grew revenue by 50% while operating losses shrunk. The key development for Kerx was the FDA approval of a second manufacturer.In August, a disruption in manufacturing cut output for Auryxia. The supply chain adjustment should prevent that from happening again. On its press release posted on November 9th, Kerx said:“Our second contract manufacturer is successfully producing Auryxia,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “We are ready to promptly make Auryxia available to pharmacies, pending approval of this manufacturer, which has a November 13, 2016 PDUFA date. “The company ended the quarter with $132 million in cash and equivalents. Of the $6.3 million in revenue, $5.1 million came from sales of Auryxia in the U.S.Kerx reported additional data for its Phase 3 clinical results for the Auryxia study in iron deficiency anemia on November 17. The positive data supports an IDA indication.Shareholders with a long term time horizon will benefit as Kerx continues ramping up sales of Auryxia.